Evidence map›Paper›PMID 31402456›Full record

ArticleCancer2019

Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.

Tengteng Wang, Lauren E McCullough, Alexandra J White, Patrick T Bradshaw, Xinran Xu, Yoon Hee Cho, Mary Beth Terry, Susan L Teitelbaum, Alfred I Neugut, Regina M Santella and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Tengteng WangDepartment of Epidemiology, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0001-9001-186X
Lauren E McCulloughDepartment of Epidemiology, Emory University, Atlanta, Georgia.
Alexandra J WhiteEpidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.
Patrick T BradshawDivision of Epidemiology, University of California, Berkeley, California.
Xinran XuDepartment of Biometrics, Roche Product Development in Asia-Pacific, Shanghai, China.
Yoon Hee ChoDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana.
Mary Beth TerryDepartment of Epidemiology, Columbia University, New York, New York.
Susan L TeitelbaumEnvironmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York.
Alfred I NeugutDepartment of Epidemiology, Columbia University, New York, New York.
Regina M SantellaDepartment of Epidemiology, Columbia University, New York, New York.
Jia ChenEnvironmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York.
Marilie D GammonDepartment of Epidemiology, University of North Carolina, Chapel Hill, North Carolina.
Columbia University · USIcahn School of Medicine at Mount Sinai · USUniversity of North Carolina at Chapel Hill · USEmory University · USNational Institute of Environmental Health Sciences · USRoche (China) · CNUniversity of California, Berkeley · USUniversity of Montana · US

Funding

True Metal fac coreP30ES009089 · NIEHS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MATTHEW S PERZANOWSKI · 1998 to 2026
$44.7M
Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
Dietary Methyl Content, Epigenetics and Breast CancerR01CA109753 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHEN, JIA · 2006 to 2010
$2.9M
BREAST CANCER AND THE ENVIRONMENT ON LONG ISLANDU01CA066572 · NCI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI GAMMON, MARILIE D · 1995 to 2004
$1.7M
NCI NIH HHS 3R01CA109753-04SNCI NIH HHS R01 CA109753NCI NIH HHS R01CA109753NCI NIH HHS R01CA66572NCI NIH HHS T32 CA057726NCI NIH HHS U01 CA066572NCI NIH HHS U01CA66572NIEHS NIH HHS ES009089NIEHS NIH HHS Intramural Z99 ES999999NIEHS NIH HHS P30 ES009089
6 · The paper itself

Abstract

backgroundThe authors hypothesized that epigenetic changes may help to clarify the underlying biologic mechanism linking aspirin use to breast cancer prognosis. To the authors' knowledge, this is the first epidemiologic study to examine whether global methylation and/or tumor promoter methylation of breast cancer-related genes interact with aspirin use to impact mortality after breast cancer.

methodsPrediagnosis aspirin use was assessed through in-person interviews within a population-based cohort of 1508 women diagnosed with a first primary breast cancer in 1996 and 1997. Global methylation in peripheral blood was assessed by long interspersed elements-1 (LINE-1) and the luminometric methylation assay. Promoter methylation of 13 breast cancer-related genes was measured in tumor by methylation-specific polymerase chain reaction and the MethyLight assay. Vital status was determined by the National Death Index through December 31, 2014 (N = 202/476 breast cancer-specific/all-cause deaths identified among 1266 women with any methylation assessment and complete aspirin data). Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs, and the likelihood ratio test was used to evaluate multiplicative interactions.

resultsAll-cause mortality was elevated among aspirin users who had methylated promotor of BRCA1 (HR, 1.67; 95% CI, 1.26-2.22), but not among those with unmethylated promoter of BRCA1 (HR, 0.99; 95% CI, 0.67-1.45; P for interaction ≤.05). Decreased breast cancer-specific mortality was observed among aspirin users who had unmethylated promotor of BRCA1 and PR and global hypermethylation of LINE-1 (HR, 0.60, 0.78, and 0.63, respectively; P for interaction ≤.05), although the 95% CIs included the null.

conclusionsThe current study suggests that the LINE-1 global methylation and promoter methylation of BRCA1 and PR in tumor may interact with aspirin use to influence mortality after breast cancer.

Indexed as

DNA MethylationEpigenesis, GeneticAdultAgedAnti-Inflammatory Agents, Non-SteroidalAspirinBRCA1 ProteinBreast NeoplasmsCause of DeathCohort StudiesFemaleGenetic Predisposition to DiseaseHumansMiddle AgedPopulation SurveillancePrognosisAnti-Inflammatory Agents, Non-SteroidalAspirinBRCA1 Proteinaspirinbreast cancerDNA methylationepigeneticmortality

Identifiers

PMID31402456
PMCPMC7147530
OpenAlexW2967264030

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.